Social JusticeGovernment Policy
News 24 of 28

ICMR Study Shows Shorter 6-Month TB Therapy Cuts Costs by ₹379 per Patient, Reduces Deaths by 30%

Target:UPSC GS-IIIMPSCSSC GATeachingPrelims HighMains MediumStatic GK Link
12 Feb 2026
~2 min
Source: Indian Express
Key Data:₹379 per patient30% of global cases64,000 cases in 202318 to 6 months9 to 6 months48,563 patients
Bodies:ICMRICMR-NIRT
Practice MCQs from today's news ▸
What This Article Covers

1.ICMR-NIRT study finds the new 6-month oral regimens (BPaL/BPaLM) for drug-resistant TB are cost-effective, saving Rs 379 per patient per healthy life-year (BPaL).

2.India reported nearly 64,000 MDR-TB cases in 2023, roughly one-third of the global burden, making this treatment shift a national priority.

3.The study validates India's 2024 policy shift in the National TB Programme to shorter regimens, which eliminates painful injections and cuts treatment duration from up to 20 months to just 6 months.

The Big Picture
Prelims · HighMains · Medium

A landmark ICMR study confirms that the new six-month oral regimens (BPaL/BPaLM) for drug-resistant TB are not only clinically effective but also cost-effective, saving lives and reducing the economic burden on patients and the health system. This is critical for India's goal to eliminate TB by 2025, as it directly tackles high treatment dropouts and catastrophic health expenditures associated with the older, longer, injectable regimens.

Exam Lens

Quick Exam Facts From News

New Treatment Duration6 months
Old Treatment Duration9-20 months
India's MDR-TB Cases (2023)~64,000 (1/3 of global)
Cost Saved (BPaL regimen)Rs 379 per patient per healthy life-year
Study Published InIndian Journal of Medical Research
Drug Regimen (Oral)Bedaquiline, Pretomanid, Linezolid (BPaL)

1-Minute Revision

  • ›New Treatment Duration: 6 months
  • ›Old Treatment Duration: 9-20 months
  • ›Target this Data: ~64,000 MDR-TB cases reported in India in 2023 (approx. 1/3rd of global burden).
  • ›Target this Nodal Body: Indian Council of Medical Research - National Institute for Research in Tuberculosis (ICMR-NIRT).
  • ›Target this Policy: Shorter 6-month oral regimens (BPaL/BPaLM) introduced in India's National TB Programme in 2024.

Mastered this topic? Test your knowledge with a full MCQ quiz.

Practice exam-style questions, track your score, and strengthen your recall.

Q1Static LinkageEasy

The Indian Council of Medical Research (ICMR), which conducted the study on TB therapy, operates under which Union Ministry?

Q2Statement-basedHard

Consider the following statements regarding the findings of the ICMR study on TB therapy:

1. The BPaL regimen was found to be cost-saving for the health programme.

2. The new shorter therapy regimens have completely replaced the use of injectable drugs.

3. India accounted for nearly half of the global multi-drug resistant TB cases in 2023.

Which of the statements given above is/are correct?

Q3Data-centricMedium

According to the ICMR study published in the Indian Journal of Medical Research, what is the duration of the new, shorter therapy for drug-resistant TB introduced in India's National TB programme in 2024?

Q4Application/ImpactMedium

What is a significant socio-economic benefit of the shift to the shorter, oral TB therapy regimen, as highlighted in the news article?

All 25 MCQs ▸
You finished this topic
Explore Related Topics
Related Current Affairs
Social Issues Current Affairs

VP Launches India Valve Registry for Heart Valve Disease Research; TN Reports 2,590 Valve Replacements in 20 Months

The Vice-President launched the India Valve Registry, a first-of-its-kind clinician-led platform to collect real-world data on valvular heart disease and interventions in India. The registry will generate India-specific evidence to improve patient care, while Tamil Nadu's CMCHIS data reveals 2,590 valve replacements in 20 months, highlighting the burden of rheumatic heart disease and the success of state-led healthcare.

Polity Current Affairs

MeitY Summons Meta Global Team Over Algorithmic Bias; Parliamentary Panel to Question

Government summons Meta's global team to clarify algorithmic bias and role in public order after MeitY rejects technical glitch explanation. Parliamentary panel will also question the company. This highlights growing regulatory scrutiny on social media algorithms and their societal impact.

Social Issues Current Affairs

NOTTO Reports 20,000+ Transplants in 2025, Launches Portal and Swap Guidelines

NOTTO released 2025 data showing over 20,000 transplants, persistent gender disparity in organ donation (68% female donors vs 78% male recipients), and launched a new digital portal to enhance transparency. New swap transplantation guidelines aim to expand matching beyond single hospitals, but legal recognition under THOTA is still pending.

Social Issues Current Affairs

Meta Trial: $567 Mn Penalty for Child Addiction, 29-State Probe on Social Media Design

A US trial against Meta over addictive social media design for children could reshape Big Tech accountability. With penalties of $567 million and a $6 million jury verdict, this case highlights the growing scrutiny of platform design and its impact on youth mental health, a key issue for GS2 (Social Justice) and GS3 (Technology).

Science & Tech Current Affairs

India's AI Pipeline: 43% Women STEM Graduates, Only 10% in Leadership – Need for Inclusive AI

India's AI ambition faces a hidden gender crisis: women drop from 43% of STEM graduates to just 10% of senior AI leadership. This pipeline leakage, driven by social barriers and digital divide, risks automating existing inequalities. For exam aspirants, this article provides critical data on gender disparity in tech and the imperative for inclusive AI development.

Science & Tech Current Affairs

Proposed Patient Data Collective (PDC) Model for Rare Diseases in India Inspired by Amul Cooperative

A new proposal suggests creating a Patient Data Collective (PDC) for rare diseases in India, modeled on the Amul dairy cooperative. This collective would pool patient data to accelerate drug discovery and clinical trials, addressing the challenge of small patient populations for rare diseases.

Science & Tech Current Affairs

ICMR Study: 61% Gram-Negative Infections Carbapenem-Resistant; Mortality 39-51%

A large ICMR study across 20 Indian hospitals (2022-2025) reveals that carbapenem-resistant Gram-negative infections cause significantly higher mortality (39-51% in bloodstream infections) and cost 1.1-2 times more to treat. The study stresses that antimicrobial resistance is a complex interplay of healthcare transmission, antibiotic pressure, and diagnostic gaps, not just antibiotic overuse.

Polity Current Affairs

Health Ministry Amends Drugs Rules, 1945: New Debarment Power for Fake Data Cases

The Health Ministry has strengthened the Drugs Rules, 1945 to penalize applicants who submit fake data for drug approvals. Previously, only rejection/cancellation was possible; now licensing authorities can debar entities from filing new applications for a period, with show-cause notice and appeal provisions. This is crucial for exam questions on regulatory frameworks, pharmaceutical governance, and the Drugs & Cosmetics Act.